Last reviewed · How we verify
BEAM conditioning
At a glance
| Generic name | BEAM conditioning |
|---|---|
| Also known as | Conditioning regimen, autologous transplantation |
| Sponsor | Andres J. M. Ferreri |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma (PHASE2)
- Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas (PHASE1, PHASE2)
- Effects of Vestibular Rehabilitation and Routine Physical Therapy in Athletes With Post Concussion Syndrome (NA)
- Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance (PHASE2)
- Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (PHASE3)
- BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease (PHASE1, PHASE2)
- Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma (PHASE2)
- Extracorporeal Shock Wave Versus Photobiomodulation Therapy for Chronic Ankle Instability (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |